Publications by authors named "Cathrine Lund Lorentzen"
Article Synopsis
- The study evaluated the long-term efficacy of a therapeutic peptide vaccine targeting IDO and PD-L1 combined with nivolumab in two patient cohorts: 30 anti-PD-1 naïve metastatic melanoma patients (cohort A) and 10 patients with progressive disease on anti-PD-1 treatment (cohort B).
- In cohort A, results showed an impressive overall response rate of 80% with 50% achieving a complete response, and median progression-free survival was approximately 25.5 months.
- In cohort B, results were less favorable, with stable disease observed in only 2 out of 10 patients, median progression-free survival of 2.4 months, and median overall survival of 16.
Article Synopsis
- The study investigated the efficacy and safety of a vaccine combining Bcl-XL-derived peptides and the adjuvant CAF09b in patients with hormone-sensitive prostate cancer, aiming to enhance immune responses against cancer cells.
- Twenty patients were divided into two groups: one received intramuscular (IM) vaccinations followed by intraperitoneal (IP), while the other group received IP first and then IM, monitoring safety and immune response.
- Results showed no serious adverse events and indicated that patients receiving the IP first demonstrated stronger and earlier immune responses, with significant activation of CD4 and CD8 T cell markers after vaccination.
Background: Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing cells could potentially restore L-arginine levels and improve anti-tumor responses. The activation of arginase-1-specific T cells may convert the immunosuppressive tumor microenvironment and induce or strengthen local Th1 inflammation.
View Article and Find Full Text PDFYears of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Technological advances have optimised mRNA-based vaccine stability, structure, and delivery methods, and multiple clinical trials investigating mRNA vaccine therapy are now enrolling patients with various cancer diagnoses.
View Article and Find Full Text PDFAnti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study ( https://clinicaltrials.
View Article and Find Full Text PDFBackground: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential in other cancer diagnoses are sparse. Further, the prospect of using checkpoint inhibitors (CPIs) to support TIL production and therapy remains to be explored.
Study Design: TIL-based ACT with CPIs was evaluated in a clinical phase I/II trial.